Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins

Summary

The non-specific binding of anticoagulantly-active heparin to plasma proteins may influence its anticoagulant effect. We used low affinity heparin (LAH) essentially devoid of anti-factor Xa activity to investigate the extent and possible mechanism of this non-specific binding. The addition of excess LAH to platelet-poor plasma containing a fixed amount of unfractionated heparin doubled the anti-factor Xa activity presumably because it displaces anticoagulantly-active heparin from plasma proteins. Although dextran sulfates of varying molecular weights also increased the anti-factor Xa activity, less sulfated heparin-like polysaccharides had no effect. These findings suggest that the ability to displace active heparin from plasma protein binding sites is related to charge and may be independent of molecular size. In contrast to its effect in plasma containing unfractionated heparin, there was little augmentation in anti-factor Xa activity when LAH was added to plasma containing low molecular weight heparin (LMWH), indicating that LMWH binds less to plasma proteins than unfractionated heparin. This concept is supported by studies comparing the anticoagulant activity of unfractionated heparin and LMWH in plasma with that in buffer containing antithrombin III. The anti-factor Xa activity of unfractionated heparin was 2-fold less in plasma than in the purified system. In contrast, LMWH had identical anti-factor Xa activity in both plasma and buffer, respectively. These findings may be clinically relevant because the recovered anti-factor Xa activity of unfractionated heparin was 33% lower in plasma from patients with suspected venous thrombosis than in plasma from healthy volunteers. The reduced heparin recovery in patient plasma reflects increased heparin binding to plasma proteins because the addition of LAH augmented the anti-factor Xa activity. In contrast to unfractionated heparin, there was complete recovery of LMWH added to patient plasma and little increase of anti-factor Xa activity after the addition of LAH. These findings may explain why LMWH gives a more predictable dose response than unfractionated heparin.

• References

• 1 Rosenberg RD. The heparin-antithrombin system: A natural anticoagulant mechanism. In: Hemostasis and Thrombosis, Basic Principles and Clinical Practise. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds) Philadelphia, Lippincott: 1987: 1373-1392
• 2 Lane DA. Heparin binding and neutralizing proteins. In: Heparin, Chemical and Biological Properties, Clinical Applications. Lane DA, Lindahl U. (eds) Boca Raton: CRC Press; 1989: 363-391
• 3 McKay EJ, Laurell CB. The interaction of heparin with plasma proteins. Demonstration of different binding sites for antithrombin III complexes and antithrombin III. Lab Clin Med 1980; 95: 69-80
• 4 Lindahl U, Backström G, Höök M, Thunberg L, Fransson LA, Linker A. Structure of the antithrombin-binding site of heparin. Proc Natl Acad Sci USA 1979; 76: 3198-3202
• 5 Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-499
• 6 Höök M, Björk I, Hopwood J, Lindahl U. Anticoagulant activity of heparin: Separation of high-activity and low-activity species by affinity chromatography on immobilized antithrombin. FEBS Lett 1976; 66: 90-93
• 7 Lam LH, Silbert JE, Rosenberg RD. The Separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-577
• 8 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Söder-ström G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Thromb Res 1979; 15: 531-541
• 9 Rucinski B, Niewiarowski S, Strzyzewski M, Holt JC, Mayo KH. Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation. Thromb Haemostas 1990; 63: 493-498
• 10 Lijnen HR, Hoylaerts M, Collen D. Mechanism and role in the neutralization of heparin in plasma. Heparin binding properties of human histidine-rich glycoprotein. J Biol Chem 1983; 258: 3803-3808
• 11 Preissner KT, Müller-Berghaus G. Neutralization and binding of heparin by S-protein/vitronectin in the inhibition of factor Xa by antithrombin III. J Biol Chem 1987; 262: 12247-12253
• 12 Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemostas 1992; 67: 639-643
• 13 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17
• 14 Lane DA, Pejler G, Glynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3980-3986
• 15 Dawes J, Pavuk N. Sequestration of therapeutic glycosaminoglycans by plasma fibronectin. Thromb Haemostas 1991; 65: 829 (abstr)
• 16 Young E, Hirsh J. Contribution of red blood cells to the saturable mechanism of heparin clearance. Thromb Haemostas 1990; 64: 559-563
• 17 Casu B, Diamantini G, Fedeli G, Mantovani M, Oreste P, Pescador R, Porta R, Prino G, Torri G, Zoppetti G. Retention of antilipemic activity by periodated-oxidized non-anticoagulant heparins. Arzneim Forsch/Drug Res 1986; 36: 637-642
• 18 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
• 19 Young E. The monitoring of low molecular weight (LMW) heparins in the clinical chemistry laboratory. Abstracts of the 4th Asian-Pacific Congress of Clinical Chemistry 1988; 160
• 20 Conard J, Brosstad F, Lie LarsenM, Samama M, Abildgaard U. Molar antithrombin III concentrations in normal human plasma. Haemostasis 1983; 13: 363-368
• 21 Lindahl U, Kjellen L. Heparin or heparan sulfate – What is the difference?. Thromb Haemostas 1991; 66: 44-48
• 22 Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787-1793
• 23 Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985; 845: 196-203
• 24 Barrowcliffe TW, Le Shirley Y. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions. Thromb Haemostas 1989; 62: 950-954
• 25 Schoen P, Lindhout T, Hemker HC. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma. Br J Haematol 1992; 81: 255-262
• 26 Béguin S, Kessels H, Dol F, Hemker HC. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity. Thromb Haemostas 1992; 68: 136-142
• 27 Barrowcliffe TW, Merton RE, Havercroft SJ, Thunberg L, Lindahl U, Thomas DP. Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides. Thromb Res 1984; 34: 125-133
• 28 Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous adminis-tration. Thromb Res 1985; 39: 631-636
• 29 Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low-molecular-weight heparin with intravenous Standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-445
• 30 Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982